Viewing Study NCT03127592


Ignite Creation Date: 2025-12-24 @ 3:16 PM
Ignite Modification Date: 2025-12-24 @ 3:16 PM
Study NCT ID: NCT03127592
Status: TERMINATED
Last Update Posted: 2023-02-09
First Post: 2017-04-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
Sponsor: Apsen Farmaceutica S.A.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module